Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 16;16(6):942-944.
doi: 10.1021/acsmedchemlett.5c00263. eCollection 2025 Jun 12.

Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways

Robert B Kargbo  1
Affiliations
Editorial

Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways

Robert B Kargbo. ACS Med Chem Lett. .

Abstract

Substituted tryptamines with selective 5-HT2A/2C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment strategies.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Agnorelli C., Spriggs M., Godfrey K., Sawicka G., Bohl B., Douglass H., Fagiolini A., Parastoo H., Carhart-Harris R., Nutt D., Erritzoe D.. Neuroplasticity and psychedelics: A comprehensive examination of classic and nonclassic compounds in pre and clinical models. Neurosci. Biobehav. Rev. 2025;172:106132. doi: 10.1016/j.neubiorev.2025.106132. - DOI - PubMed
    1. Modzelewski S., Stankiewicz A., Waszkiewicz N., Łukasiewicz K.. Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes. Neuropharmacology. 2025;271:110402. doi: 10.1016/j.neuropharm.2025.110402. - DOI - PubMed
    1. Omidian H., Omidian A.. The emergence of psilocybin in psychiatry and neuroscience. Pharmaceuticals. 2025;18:555. doi: 10.3390/ph18040555. - DOI - PMC - PubMed
    1. Schenberg E. E.. From efficacy to effectiveness: Evaluating psychedelic randomized controlled trials for trustworthy evidence-based policy and practice. Pharmacol. Res. Perspect. 2025;13:e70097. doi: 10.1002/prp2.70097. - DOI - PMC - PubMed
    1. Thomson, S. ; Thomacos, N. . Utilizing psychedelics to enhance well-being: A systematic review. J. Psychoactive Drugs 2025, 1 10.1080/02791072.2025.2484380. - DOI - PubMed

Publication types

LinkOut - more resources